REPORTS

Let’s Pullulate and Expand Your Business

Metabolic Disorders Drugs Market - Global Professional Analysis and Forecast to 2026

Nov 15, 2019  |  189 PAGES  |  REPORT CODE: CMM237252
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Metabolic Disorders Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.1% during the forecast period.

This report presents the market size and development trends by detailing the Metabolic Disorders Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Metabolic Disorders Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Metabolic Disorders Drugs industry and will help you to build a panoramic view of the industrial development.

Metabolic Disorders Drugs Market, By Type:

  • Tablet

  • Injection

Metabolic Disorders Drugs Market, By Application:

  • Diabetes

  • Disorders of the Thyroid and Pituitary Gland

  • Other

Some of the leading players are as follows:

  • Zealand Pharma

  • Mitobridge

  • Outpost Medicine

  • PerkinElmer

  • Exelixis, Inc.

  • Verva Pharmaceuticals

  • Rhythm

  • Zafgen

  • OxThera

  • Anchor Therapeutics

  • Biophytis

  • Eternygen

  • MedGenome

  • CellCentric

  • Biophytis

  • Nimbus Therapeutics

  • Pronutria Biosciences

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Metabolic Disorders Drugs Market: Technology Type Analysis

  • 4.1 Metabolic Disorders Drugs Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Metabolic Disorders Drugs Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Tablet

    • 4.3.2 Injection

5 Metabolic Disorders Drugs Market: Product Analysis

  • 5.1 Metabolic Disorders Drugs Product Market Share Analysis, 2018 & 2026

  • 5.2 Metabolic Disorders Drugs Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Metabolic Disorders Drugs Market: Application Analysis

  • 6.1 Metabolic Disorders Drugs Application Market Share Analysis, 2018 & 2026

  • 6.2 Metabolic Disorders Drugs Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Diabetes

    • 6.3.2 Disorders of the Thyroid and Pituitary Gland

    • 6.3.3 Other

7 Metabolic Disorders Drugs Market: Regional Analysis

  • 7.1 Metabolic Disorders Drugs Regional Market Share Analysis, 2018 & 2026

  • 7.2 Metabolic Disorders Drugs Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Zealand Pharma

    • 9.1.1 Zealand Pharma Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Mitobridge

    • 9.2.1 Mitobridge Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Outpost Medicine

    • 9.3.1 Outpost Medicine Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 PerkinElmer

    • 9.4.1 PerkinElmer Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Exelixis, Inc.

    • 9.5.1 Exelixis, Inc. Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Verva Pharmaceuticals

    • 9.6.1 Verva Pharmaceuticals Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Rhythm

    • 9.7.1 Rhythm Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Zafgen

    • 9.8.1 Zafgen Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 OxThera

    • 9.9.1 OxThera Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Anchor Therapeutics

    • 9.10.1 Anchor Therapeutics Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Biophytis

    • 9.11.1 Biophytis Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Eternygen

    • 9.12.1 Eternygen Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 MedGenome

    • 9.13.1 MedGenome Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 CellCentric

    • 9.14.1 CellCentric Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Biophytis

    • 9.15.1 Biophytis Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Nimbus Therapeutics

    • 9.16.1 Nimbus Therapeutics Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Pronutria Biosciences

    • 9.17.1 Pronutria Biosciences Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

 

The List of Tables and Figures (Totals 97 Figures and 139 Tables)

  • Figure Tablet Metabolic Disorders Drugs market, 2015 - 2026 (USD Million)

  • Figure Injection Metabolic Disorders Drugs market, 2015 - 2026 (USD Million)

  • Figure Diabetes market, 2015 - 2026 (USD Million)

  • Figure Disorders of the Thyroid and Pituitary Gland market, 2015 - 2026 (USD Million)

  • Figure Other market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Metabolic Disorders Drugs market, by country, 2015 - 2026 (USD Million)

  • Table North America Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table North America Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table North America Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Canada Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Canada Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Europe Metabolic Disorders Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Europe Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Europe Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Europe Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Germany Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Germany Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table France Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table France Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Italy Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Italy Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Spain Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Spain Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Metabolic Disorders Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table China Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table China Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Japan Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Japan Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table India Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table India Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Metabolic Disorders Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table MEA Metabolic Disorders Drugs market, by country, 2015 - 2026 (USD Million)

  • Table MEA Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table MEA Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table MEA Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Metabolic Disorders Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Metabolic Disorders Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Metabolic Disorders Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Zealand Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Mitobridge Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Outpost Medicine Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table PerkinElmer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Exelixis, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Verva Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Rhythm Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Zafgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table OxThera Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Anchor Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biophytis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eternygen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table MedGenome Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table CellCentric Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biophytis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Nimbus Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pronutria Biosciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top